Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Blockchain Press Releases

Piramal Pharma Limited Announces Consolidated Results for Q1FY24

Published

on

piramal-pharma-limited-announces-consolidated-results-for-q1fy24

MUMBAI, India, Aug. 3, 2023 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), today announced its consolidated results for the first quarter (Q1) ended 30th June 2023.

 

 

Consolidated Financial Highlights

(In INR Crores)

Particulars

Q1

FY24

Q1

FY23

YoY Growth

Q4

FY23

QoQ Growth

Revenue from Operation

1,749

1,482

18 %

2,164

-19 %

   CDMO

898

770

17 %

1,285

-30 %

   Complex Hospital Generic (CHG)

617

508

22 %

702

-12 %

   India Consumer Healthcare (ICH)

239

211

13 %

206

16 %

EBITDA

171

89#

92 %

376

-55 %

EBITDA Margin

10 %

6 %

17 %

PAT

-99

-109

NA

50

-297 %

PAT Margin

-6 %

-7 %

2 %

# Q1 FY23 EBITDA had one-time inventory margin impact of INR 68 Crore

Key Highlights for Q1FY24

  • Revenue from Operation grew by 18% YoY in Q1FY24 driven by broad base performance across all three businesses – CDMO, CHG and ICH
  • EBITDA margin in Q1FY24 was 10%, a YoY improvement compared to 6% in Q1FY23, driven by healthy revenue growth and cost optimization measures 
  • We maintain our quality track record of zero OAIs (Official Action Indicated) as we successfully closed the US FDA inspection at the Pithampur facility with zero observations
  • We strengthened our Management Team by appointing Jeffrey Hampton as President & Chief Operating Officer for Piramal Critical Care (CHG business)
  • We have shared the details of our Rights Issue – Rights Price of INR. 81, Record Date of August 2, 2023 and Entitlement Ratio of 5:46

Nandini Piramal, Chairperson, Piramal Pharma Limited said, “We had a positive start to the new financial year with healthy revenue growth and improvement in our EBITDA margins. Our CDMO business is also witnessing continued order inflows, especially for our differentiated offerings and innovation related work. Our Inhalation Anesthesia portfolio is seeing a healthy demand and our India Consumer Healthcare business is delivering good growth driven by power brands. We continue to maintain our best-in-class quality track record and are also taking multiple initiatives in the area of ESG to grow our business responsibly.
Historically our H2 has been better than H1, both in terms of revenue and profitability. We are working to leverage our good start to the financial year and continuing this momentum to deliver a healthy YoY performance for the rest of the year. We believe in the growth potential of our business and are accordingly executing on our strategic priorities to create shareholder value. Our promoter and promoter group have agreed to subscribe to the extent of 100% of the equity shares offered in our Rights Issue, thereby reaffirming their confidence in the underlying strengths of our business.”

Key Business Highlights for Q1FY24

 

Contract Development and Manufacturing Organization (CDMO):

  • Witnessed continued order inflow momentum and strong execution in Q1FY24. Continue to see good demand for our differentiated offering in the niche areas of high potent API, peptide, anti-body drug conjugate (ADC) and development and manufacturing of on-patent API
  • Recently expanded capacities at sites with differentiated offering witnessing encouraging customer demand
  • Capacity expansion for antibody drug conjugate (ADC) at Grangemouth facility to strengthen our position in the ADC market
  • YoY improvement in demand for our generic API business
  • Maintained our quality track record – Successfully cleared 8 regulatory inspections (including an US FDA inspection at our Pithampur facility) and multiple customer audits in Q1FY24
  • Cost optimization, strategizing procurement and operational excellence initiatives helping to mitigate inflationary pressures and improve profitability

 

Complex Hospital Generics (CHG):

  • Continued momentum in Inhalation Anesthesia (IA) sales, mainly led by strong demand for Sevoflurane
  • Expanding inhalation anesthesia capacity to meet the growing demand
  • Intrathecal portfolio in the US continue to command leading market share
  • Building a pipeline of 27+ new products which are various stages of development. Launched 1 new product during Q1FY24
  • Appointed Jeffrey Hampton as President & Chief Operating Officer of CHG Business. Jeff has previously worked with Accord Healthcare, Inc. and Apotex Inc.  

 

India Consumer Healthcare (ICH):

  • 11 new products and 3 new SKUs launched during Q1FY24
  • Continue to invest in media and trade spends to drive growth in power brands
  • Power Brands – Littles, Lacto Calamine, Polycrol, Tetmosol and I-range, grew by 15% YoY in Q1FY24 and contribute to 43% of ICH sales
  • E-commerce grew by more than 18% YoY in Q1FY24
  • Wide distribution reach across general trade and are also strengthening our presence in alternate channels of distribution including e-commerce, modern trade, and having our own direct-to-customer website -Wellify.in

 

 

Consolidated Profit and Loss Statement

(In INR Crores)

Reported Financials

Particulars

Q1FY24

Q1FY23

YoY  Change

Q4FY22

QoQ  Change

Revenue from Operations

1,749

1,482

18 %

2,164

-19 %

Other Income

38

72

-47 %

25

56 %

Total Income

1,787

1,554

15 %

2,188

-18 %

Material Cost

627

574

9 %

840

-25 %

Employee Expenses

496

461

8 %

474

5 %

Other Expenses

494

430

15 %

499

-1 %

EBITDA

171

89#

92 %

376

-55 %

Finance Cost

119

62

90 %

104

14 %

Depreciation

174

162

7 %

184

-6 %

Share of net profit of associates

14

20

-28 %

8

85 %

Profit Before Tax

-107

-115

-7 %

95

-213 %

Tax

-9

-6

NA

45

-119 %

Net Profit after Tax

-99

-109

NA

50

-297 %

Exceptional item

0

0

0

Net Profit after Tax after exceptional item

-99

-109

NA

50

-297 %

 # Q1 FY23 EBITDA had one-time inventory margin impact of INR 68 Crore

Q1FY24 Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on 4th August 2023 at 10:00 AM (IST) to discuss its Q1FY24 Results. 

The dial-in details for the call are as under:

Event

Location & Time

Telephone Number

Conference call on
4th August, 2023

India – 10:00 AM IST

+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)

1 800 120 1221 (Toll free number)

USA – 12:30 AM

(Eastern Time – New York)

Toll free number

18667462133

UK – 5:30 AM

(London Time)

Toll free number

08081011573

Singapore – 12:30 PM

(Singapore Time)

Toll free number

8001012045

Hong Kong – 12:30 PM

(Hong Kong Time)

Toll free number

800964448

Express Join with Diamond Pass™

Please use this link for prior registration to reduce wait time at the time of joining the call –https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9503078&linkSecurityString=33aa158d84

About Piramal Pharma Ltd:

Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, one of PPL’s associate companies, Allergan India Private Limited is a JV with AbbVie Inc. and has emerged as one of the market leaders in the ophthalmology therapy area. Further, PPL has a minority investment in Yapan Bio Private Limited. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.

For more information visit: www.piramaI.com/pharma I I inker1ln | Facebook I Twitter.

Photo: https://mma.prnewswire.com/media/2169456/Nandini_Piramal.jpg
Logo: https://mma.prnewswire.com/media/1855206/4196563/Piramal_Pharma_Limited_Logo.jpg

 

Piramal Pharma Limited Logo

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q1fy24-301893273.html

Continue Reading

Blockchain Press Releases

HTX Collaborates with Astar Network to Accelerate Blockchain Innovation through the TGE Catalyst Grant

Published

on

htx-collaborates-with-astar-network-to-accelerate-blockchain-innovation-through-the-tge-catalyst-grant

SINGAPORE, May 8, 2024 /PRNewswire/ — The leading digital assets exchange HTX has collaborated with Astar Network, a blockchain that aims to become Polkadot’s “smart contract hub” and serves as a parachain for Polkadot, in support of its newly launched “TGE Catalyst Grant. This initiative marks a significant step forward in fostering innovation within the blockchain ecosystem, particularly through the Astar zkEVM platform.

The TGE Catalyst Grant is designed to empower emerging projects preparing for their Token Generation Events (TGE) on Astar’s zkEVM. This groundbreaking program provides a holistic support package that includes financial assistance, strategic collaboration with key opinion leaders, and robust marketing campaigns, all aimed at ensuring successful token launches.

“As an active participant in the blockchain sector, HTX is committed to supporting transformative projects that drive the industry forward. Our collaboration with Astar Network through the TGE Catalyst Grant underscores our HTX Ventures’ dedication to nurturing innovation and providing comprehensive market support from the outset,” said Edward, Managing Partner of HTX Ventures. “We are excited to work alongside Astar Network and other leading exchanges to facilitate a new generation of token projects, ensuring they have the tools and support needed to succeed.”

HTX Ventures, the global investment arm of the HTX, has been an investor in Astar Network since 2021, demonstrating a long-term commitment to the growth and success of Astar’s platform and its associated projects.

“We are deeply grateful for the support from HTX and their belief in our vision to expand the frontiers of blockchain technology.” said Astar Network, “This collaboration through the TGE Catalyst Grant not only accelerates our mission at Astar Network but also cultivates significant synergies that will enhance our joint efforts to drive global blockchain innovation. We are excited about the future and look forward to working together to bring about transformative impacts within the ecosystem.”

Key features of the TGE Catalyst Grant include:

  • Strategic CEX Collaboration: Streamlining the listing process and boosting market momentum through collaborations with top CEXs including HTX.
  • Unique Marketing and KOL Alliances: Utilizing Astar’s “SAMURAI Support” marketing framework to enhance project visibility and engagement within the Web3 community.
  • Listing Acceleration Package: Offering financial support for marketing and promotional activities on CEXs, alongside liquidity advisory services and audit support to ensure project readiness and security.

HTX’s involvement in the TGE Catalyst Grant not only strengthens its portfolio of innovative blockchain services but also enhances its role as a catalyst in the decentralized finance (DeFi) landscape.

About HTX:

Founded in 2013, HTX has evolved over a decade from a simple cryptocurrency exchange to a comprehensive blockchain business ecosystem. This expansion covers a wide range of services including digital asset trading, financial derivatives, wallets, research, investments, incubation, and more. As a world-leading portal to Web 3.0, HTX is committed to a growth strategy focused on global expansion, ecological prosperity, wealth effect, and safety and compliance. This approach enables us to offer comprehensive, safe, and reliable services and value to virtual currency enthusiasts around the world, reinforcing our position as a global gateway to Web3.

Contact Details

Michael Wang
[email protected]

Company Website
https://www.htx.com/

About Astar:

Astar Network is the gateway for projects across enterprises, entertainment & gaming in Japan and beyond, driving global adoption and delivering web3 to billions. It leverages a cross-virtual machine powered by Polygon and Polkadot to offer customizable blockchain solutions that accelerate web3 adoption. With zk-powered Ethereum L2 Scaling (zkEVM), EVM, WASM, and a cutting-edge ecosystem, Astar delivers robust, secure, and interoperable web3 technology.

Astar zkEVM is the new Layer-2 solution to scale a web3 experience on Ethereum with zero knowledge (ZK) technology. Astar Network connects you to web3.

Photo – https://mma.prnewswire.com/media/2407910/HTX_Astar.jpg
Logo – https://mma.prnewswire.com/media/2391903/image_ID__Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/htx-collaborates-with-astar-network-to-accelerate-blockchain-innovation-through-the-tge-catalyst-grant-302140043.html

Continue Reading

Blockchain

Omnichain protocols offer the answer to blockchain fragmentation

Published

on

omnichain-protocols-offer-the-answer-to-blockchain-fragmentation

Blockchain fragmentation, stemming from the proliferation of diverse blockchain networks, poses challenges for interoperability and seamless data exchange. In response, omnichain protocols emerge as a solution to bridge these fragmented ecosystems.

These protocols aim to create a unified framework that enables communication and data transfer across multiple blockchain networks. By establishing common standards and protocols, omnichain solutions facilitate interoperability, allowing different blockchains to interact seamlessly.

The adoption of omnichain protocols addresses key issues such as data silos, redundant processes, and inefficiencies caused by blockchain fragmentation. These protocols enable businesses and developers to leverage the strengths of various blockchain networks while mitigating the drawbacks of fragmentation.

With omnichain protocols, organizations can achieve greater flexibility, scalability, and efficiency in their blockchain implementations. These protocols provide a foundation for building interconnected blockchain ecosystems, fostering innovation and collaboration across industries.

As blockchain technology continues to evolve, omnichain protocols play a vital role in overcoming the challenges of blockchain fragmentation and unlocking the full potential of distributed ledger technology.

Source: cointepegraph.com

The post Omnichain protocols offer the answer to blockchain fragmentation appeared first on HIPTHER Alerts.

Continue Reading

Blockchain

State-owned German Bank Set to Introduce Blockchain-Backed Digital Bonds

Published

on

state-owned-german-bank-set-to-introduce-blockchain-backed-digital-bonds

Germany’s state-owned bank, Kreditanstalt fuer Wiederaufbau (KfW), is set to embrace the digital age by issuing its first blockchain-based digital bond. This move signals the bank’s foray into blockchain technology and its commitment to driving its adoption in the financial sector.

The bond that KfW plans to issue will be tokenized, marking it as a ‘crypto security.’ This tokenization involves representing the bond on a blockchain, enabling validation of its transactional history and ownership.

Tokenizing bonds offers several advantages, including the automation of various aspects of bond management such as interest payments and maturity settlements. Additionally, it reduces the need for intermediaries in the process, thereby cutting down on overall transaction costs.

Melanie Kehr, a member of the Executive Board of KfW Group, expressed the bank’s innovative approach in testing new financial market products. She emphasized that the issuance of the digital bond under the German Electronic Securities Act reflects the bank’s commitment to exploring innovative solutions in the financial market.

The issuance of the blockchain-based bond marks a significant step for KfW, as it seeks to attract investors and enhance efficiency and scalability in bond transactions. Tim Armbruster, Treasurer at KfW, highlighted the importance of digitalization in increasing efficiency and scalability, emphasizing the bank’s goal of attracting a wide range of investors for the digital bond.

KfW plans to engage in dialogues with institutional investors in Europe to better understand their needs and explore the potential of blockchain technology in fintech. Cashlink Technologies GmbH, a Frankfurt-based fintech company, will serve as the crypto securities registrar for KfW, facilitating the issuance of the digital bond.

The decision by KfW to issue a blockchain-based digital bond underscores the growing interest in blockchain technology within the financial sector. It represents a significant step towards leveraging blockchain for innovation and efficiency in financial markets.

Source: cryptonews.com

 

The post State-owned German Bank Set to Introduce Blockchain-Backed Digital Bonds appeared first on HIPTHER Alerts.

Continue Reading
Advertisement
Advertisement

Latest News

Recent Listings

  • Global Payout, Inc.

    Since the Company’s inception in 2009, Global Payout, Inc. has been a leading provider of compreh...

  • MTrac Tech Corp.

    MTrac Tech Corporation, a Nevada Corporation, is a privately held, wholly owned subsidiary of Glo...

  • Net1

    Net1 is a leading provider of transaction processing services, financial inclusion products ...

  • uBUCK Technologies SEZC

    Based in Georgetown, Cayman Islands, uBUCK Tech is a fintech enterprise that specializes in digit...

  • LiteLink Technologies Inc.

      LiteLink is a major player in developing world-class enterprise platforms that utilize ar...

  • Good Gamer Corp.

      Good Gamer Corp. is a privately-held technology company focusing on gamers and streamers....

  • BitPay

      Founded in 2011, BitPay pioneered blockchain payment processing with the mission of trans...

  • About Net1

      Net1 is a leading provider of transaction processing services, financial inclusion produc...

  • Blockchain Foundry Inc.

    Headquartered in Toronto, Canada, Blockchain Foundry (CSE:BCFN)(FWB:8BF)(OTC:BLFDF) is a global b...

  • Sixgill

    Sixgill provides a full suite of universal data automation and authenticity products and services...

Trending on TBE